Physician profile
Stanley Bykov
NPI 1972539112
$12,399.06
in general payments reported to CMS, 2019-2025
29 companies · $2,300 in 2025
The $2,300 reported for 2025 was more than what 89% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $715 · 2020: $445 · 2021: $689 · 2022: $1,246 · 2023: $4,680 · 2024: $2,325 · 2025: $2,300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,467 · Honoraria: $1,838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,467.08 |
| Honoraria | $1,837.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $2,660.20 | 2022-2023 | Tepezza |
| Bausch & Lomb Americas INC. | $1,406.55 | 2022-2025 | Xiidra, Miebo, Envista Mx60 Iol |
| Amgen INC. | $1,093.66 | 2024-2025 | Tepezza |
| Abbvie INC. | $976.53 | 2022-2025 | Vuity, Lumigan, Ozurdex |
| Alcon Vision LLC | $856.43 | 2022-2025 | Rocklatan, Rhopressa, Simbrinza |
| Glaukos Corporation | $681.21 | 2019-2024 | Idose |
| Novartis Pharmaceuticals Corporation | $594.72 | 2019-2023 | |
| Harrow Eye, LLC | $518.66 | 2023-2025 | Vevye |
| Regeneron Healthcare Solutions, INC. | $443.54 | 2023-2025 | Eylea Hd, Eylea |
| Allergan, INC. | $410.88 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $372.28 | 2024-2025 | Xdemvy |
| Eyevance Pharmaceuticals LLC | $282.37 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $258.81 | 2019-2025 | Cequa |
| Apellis Pharmaceuticals, INC. | $246.10 | 2023-2025 | Syfovre |
| Thea Pharma INC. | $203.54 | 2024-2025 | Iyuzeh |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $194.57 | 2023-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $167.83 | 2019-2021 | |
| Oyster Point Pharma, INC. | $158.97 | 2022-2023 | Tyrvaya |
| Mallinckrodt Hospital Products INC. | $150.00 | 2021 | |
| Kala Pharmaceuticals, INC. | $148.34 | 2019-2022 | |
| Dompe US, INC. | $121.45 | 2024-2025 | Oxervate |
| Akorn, INC. | $115.12 | 2020 | |
| Ocular Therapeutix, INC. | $61.41 | 2023-2024 | Dextenza |
| Johnson & Johnson Surgical Vision, INC. | $60.57 | 2025 | Tecnis Simplicity |
| Genentech USA, INC. | $57.36 | 2023-2024 | Vabysmo |
| Sight Sciences, INC. | $56.57 | 2021-2023 | Tearcare System |
| Lkc Technologies, INC. | $52.71 | 2025 | |
| Rayner Intraocular Lenses Limited | $26.66 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Astellas Pharma US INC | $22.02 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Bykov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.